What are the most common mistakes with Tirzepatide?
The most common Tirzepatide mistakes are titrating too fast; not lifting / eating protein during the cut; stopping cold turkey without a maintenance plan. Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for Tirzepatide is limited.
Common Tirzepatide mistakes
- Titrating too fast
- Not lifting / eating protein during the cut
- Stopping cold turkey without a maintenance plan
Bloodwork worth tracking
- Lipid panel
- ALT/AST
- A1C if relevant
References
- Tirzepatide Once Weekly for Treatment of Obesity (SURMOUNT-1) — Jastreboff AM et al., NEJM, 2022
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) — Frías et al., N Engl J Med, 2021
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial — Garvey et al., Lancet, 2023
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Tirzepatide
Full Tirzepatide breakdownTirzepatide what it's used forTirzepatide side effectsTirzepatide how to take itTirzepatide who should avoid itTirzepatide half-lifeTirzepatide how long to workTirzepatide legal statusTirzepatide how it workstirzepatide vs semaglutideretatrutide vs tirzepatidetirzepatide vs cagrilintidevk2735 vs tirzepatideAsk the AI Coach
Last updated 2026-06-15.